Harriet Feilotter

Dr. Feilotter focuses on the development and validation of biomarkers to be used in the screening, diagnosis or treatment of human diseases, including cancer.  

Her research includes the study of DNA, RNA and protein biomarkers in diseases ranging from cancer (breast, brain, melanoma, bladder, colon, CLL) to major depression. She is currently focused on the use of circulating biomarkers such as miRNA and protein species that can be found in the plasma of patients. Profiling these molecules, and then integrating the information from multiple types of biomarkers to provide information about disease state or likely response to therapy is the primary goal of these studies.

Dr. Feilotter makes use of multiple platforms, including next generation sequencing, quantitative mass spectrometry, real time PCR and microarray to generate targeted biomarker data. She also has an emerging interest and focus in informatics, including the proper handling and storage of biomarker data, the preprocessing pipelines required to ensure high quality data, and the analytic pipelines needed to deliver an effective clinical tool.